Method for producing pharmaceutical composition containing sitagliptin phosphate anhydride with improved tableting problems

The use of melt granulation and external lubrication methods in producing sitagliptin phosphate tablets addresses sticking issues, ensuring smooth tableting and improved tablet surface quality.

JP2024169250APending Publication Date: 2024-12-05NIHON GENERIC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023095890
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing methods for producing sitagliptin phosphate tablets face tableting problems such as sticking, which results in a glossy surface and adhesion to the punch during compression molding.

Method used

A pharmaceutical composition containing sitagliptin phosphate anhydride is produced using a melt granulation method followed by external lubrication, or a fluidized bed granulation method combined with external lubrication, to prevent sticking and improve tableting suitability.

Benefits of technology

The methods effectively eliminate tableting failures by preventing sticking and ensuring a smooth tablet surface without adhesion to the punch, enhancing the overall tableting process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169250000001
    Figure 2024169250000001
  • Figure 2024169250000002
    Figure 2024169250000002
  • Figure 2024169250000003
    Figure 2024169250000003
Patent Text Reader

Abstract

To provide a method for producing pharmaceutical composition containing sitagliptin phosphate anhydride with improved tableting problems.SOLUTION: The present invention provides a method for producing a pharmaceutical composition, includes the steps of: granulating a mixture containing sitagliptin phosphate anhydrate and one or more additives, in which a granulation method being a melt granulation method, and comprising mixing an additive with the obtained granules; and compressing the obtained mixture to obtain plain tablets.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing a pharmaceutical composition containing sitagliptin phosphate anhydrate, which has improved tableting trouble. [Background technology]

[0002] The chemical name of sitagliptin is (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine, and tablets containing sitagliptin phosphate hydrate as the active ingredient are known to be antidiabetic agents and are sold as Januvia (registered trademark) tablets 12.5 mg / 25 mg / 50 mg / 100 mg or Glactiv (registered trademark) tablets 12.5 mg / 25 mg / 50 mg / 100 mg (Non-patent literature 1, 2).

[0003] The indication is "type 2 diabetes mellitus," and the dosage is usually 50 mg of sitagliptin orally administered once a day to adults. If the effect is insufficient, the dosage can be increased to 100 mg once a day while closely monitoring the progress.

[0004] At present, sitagliptin phosphate hydrate is provided in the form of tablets to medical facilities in Japan. The formulations and manufacturing methods of preparations containing sitagliptin or its salts are disclosed in the following Patent Documents 1 to 3, but the number of such documents is currently small. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Special Publication No. 2007-504230 [Patent Document 2] JP 2019-172672 A [Patent Document 3] JP 2020-121950 A [Non-patent literature]

[0006] [Non-Patent Document 1] Package insert "Januvia Tablets 12.5 mg / 25 mg / 50 mg / 100 mg", revised March 2020 (2nd edition) [Non-Patent Document 2] Package insert "Glactiv Tablets 12.5mg / 25mg / 50mg / 100mg", revised March 2020 (2nd edition) Summary of the Invention [Problem to be solved by the invention]

[0007] An object of the present invention is to provide a method for producing a pharmaceutical composition containing sitagliptin phosphate anhydrate, which has improved tableting trouble. [Means for solving the problem]

[0008] The inventors of the present invention have found that tableting problems can be eliminated by producing a pharmaceutical composition for solid preparations containing sitagliptin phosphate anhydrous and one or more additives by a melt granulation method, and have completed the present invention. In addition, the inventors have found that tableting problems can be eliminated by producing a pharmaceutical composition for solid preparations containing sitagliptin phosphate anhydrous by a fluidized bed granulation method and tableting using an external lubrication method, and have completed the present invention.

[0009] That is, the present invention provides (1) A process for granulating a mixture containing sitagliptin phosphate anhydrous and one or more additives, characterized in that the granulation method is a melt granulation method; mixing the obtained granules with additives; A step of compressing the obtained mixture to obtain plain tablets. A method for producing a pharmaceutical composition comprising: (2) A step of granulating a mixture containing sitagliptin phosphate anhydrous and one or more additives, characterized in that the granulation method is a fluidized bed granulation method; mixing the obtained granules with additives; A process in which a lubricant is applied to the surface of the punch and the wall of the die of the compression molding machine without mixing with other ingredients, and the granules are compressed and molded by the external lubrication method to obtain plain tablets. A method for producing a pharmaceutical composition comprising: (3) The method according to (1), in which one of the additives is a low melting point substance and the granules are produced by a melt granulation method; (4) The method according to (3), wherein the low melting point substance is glycerin monostearate. (5) The method according to any one of (1) to (2) above, wherein the pharmaceutical composition is a tablet. This is regarding. Effect of the Invention

[0010] According to the present invention, there can be provided a method for producing a pharmaceutical composition containing sitagliptin phosphate anhydrate which exhibits good suitability for tableting and reduces tableting problems. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] In the present invention, the "tabletting problem" includes, for example, sticking.

[0012] Sticking is a phenomenon in which part of the tablet surface peels off and adheres to the punch during the process of compressing and tableting a pharmaceutical composition.

[0013] In the present invention, "improvement of tableting troubles" refers to, for example, the absence of gloss on the tablet surface and the absence of adhesion and cloudiness on the surface of the compression molding part of the punch due to sticking. The occurrence of tableting troubles is evaluated, for example, by visual inspection of the tablet appearance and the punch.

[0014] In this specification, D90 refers to the volume-based particle size measured by a laser diffraction method. In principle, it means the particle size at the time when particles of a certain volume are sieved in ascending order of size and the particles that make up 90% of the volume are separated.

[0015] In this specification, D50 refers to the volume-based particle size measured by a laser diffraction method. In principle, it means the particle size at the time when particles of a certain volume are sieved in ascending order of size and the particles that make up 50% of the volume are separated.

[0016] In this specification, D10 refers to a volume-based particle size measured by a laser diffraction method. In principle, it means the particle size at the time when particles of a certain volume are sieved in ascending order of size and the particles corresponding to 10% of the volume are separated.

[0017] The method for producing a pharmaceutical composition containing sitagliptin phosphate anhydride having improved tableting trouble according to the present invention will be described below.

[0018] The sitagliptin phosphate anhydride used in the present invention can be prepared, for example, according to the method described in Japanese Patent No. 3,762,407.

[0019] The amount of sitagliptin in the pharmaceutical composition is not particularly limited as long as it is the amount of sitagliptin in the formulation that constitutes the dosage of a pharmaceutical preparation, for example, 2 to 60% by weight in one embodiment, 5 to 50% by weight in one embodiment, and 10 to 40% by weight in one embodiment based on the total amount of the pharmaceutical composition.

[0020] From the viewpoint of production suitability, the D90 of the sitagliptin phosphate anhydrate used in the present invention is, in one embodiment, 1 μm or more and 200 μm or less, in one embodiment, 5 μm or more and 150 μm or less, and in one embodiment, 10 μm or more and 100 μm or less.

[0021] From the viewpoint of production suitability, the D50 of the sitagliptin phosphate anhydrate used in the present invention is, in one embodiment, 0.5 μm or more and 150 μm or less, in one embodiment, 1 μm or more and 100 μm or less, and in one embodiment, 5 μm or more and 50 μm or less.

[0022] From the viewpoint of production suitability, D10 of the sitagliptin phosphate anhydride used in the present invention is in one embodiment 0.1 μm or more and 100 μm or less, in one embodiment 0.2 μm or more and 50 μm or less, and in one embodiment 0.5 μm or more and 25 μm or less.

[0023] In the melt granulation method used in the present invention, a granulated product can be obtained by mixing a drug, a low melting point substance, and other additives as necessary, and melting them at a high temperature. There are no particular limitations on the low melting point substance, so long as it is an additive that has a low melting point and has the function of adhering powder when melted.

[0024] The low melting point substance used in the present invention is not particularly limited as long as it is pharma- ceutical acceptable. Characteristically, the upper limit of the melting point of the low melting point substance used in the present invention is 80°C or less in one embodiment, 75°C or less in one embodiment, and 70°C or less in one embodiment. The lower limit is 40°C or more, and can be defined as the lower limit of each embodiment. Specifically, for example, the low melting point substance includes one or more substances selected from the group consisting of glycerin monostearate, glycerin fatty acid ester, hardened oil, polyethylene glycol, stearyl alcohol, polyoxyl 40 stearate, and polyoxyethylene polyoxypropylene glycol. In one embodiment, the low melting point substance is glycerin monostearate.

[0025] In the fluidized bed granulation method used in the present invention, a granulated product can be obtained by mixing a drug and, if necessary, other additives, and spraying a granulation liquid (aqueous solution) containing a binder or water.

[0026] In the external lubrication method used in the present invention, a lubricant is applied to the surface of the punch and the wall of the die of the compression molding machine beforehand without mixing with other ingredients when compressing the pharmaceutical composition, and then the composition is compressed to obtain tablets. The external lubrication method uses an external lubrication device having a mechanism for applying the lubricant to the surface of the punch and the wall of the die of the compression molding machine beforehand.

[0027] The lubricant used in the external lubrication method is not particularly limited as long as it is pharma- ceutically acceptable.Specific examples include one or more additives selected from the group consisting of stearic acid, magnesium stearate, sodium stearate, calcium stearate, talc, and sodium stearyl fumarate.In one embodiment, the lubricant is magnesium stearate and / or sodium stearyl fumarate.

[0028] The pharmaceutical composition of the present invention may contain pharmaceutical additives as needed.Specific examples of such additives include excipients, binders, disintegrants, lubricants, surfactants, flow agents, coating agents, acidulants, foaming agents, sweeteners, flavorings, colorants, buffers, and antioxidants.As for lubricants, lubricants used in the external lubrication method may also be added as needed in methods other than the external lubrication method.

[0029] Examples of excipients include D-mannitol, corn starch, crystalline cellulose, trehalose, anhydrous calcium hydrogen phosphate, D-sorbitol, lactose, sucrose, starch, pregelatinized starch, low-substituted hydroxypropylcellulose, sodium carmellose, light anhydrous silicic acid, synthetic aluminum silicate, magnesium aluminometasilicate, gum arabic, dextrin, and pullulan.

[0030] Examples of disintegrants include corn starch, potato starch, low-substituted hydroxypropyl cellulose, sodium starch glycolate, carmellose, carmellose calcium, hydroxypropyl starch, croscarmellose, croscarmellose sodium, crospovidone, pregelatinized starch, and the like.

[0031] Examples of binders include hydroxypropyl cellulose, hypromellose, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol graft copolymer, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, low-substituted hydroxypropyl cellulose, gum arabic, and hydroxyethyl cellulose.

[0032] Examples of lubricants include stearic acid, magnesium stearate, sodium stearate, calcium stearate, talc, sodium stearyl fumarate, hardened oil, and sucrose fatty acid ester.

[0033] Examples of the surfactant include polysorbate 80, sodium lauryl sulfate, polyoxyethylene hydrogenated castor oil, and the like.

[0034] Examples of the fluidizing agent include light anhydrous silicic acid and talc.

[0035] Examples of coating agents include hypromellose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, polyvinyl alcohol-polyethylene glycol graft copolymer, polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer, polyethylene glycol, glycerin monostearate, titanium oxide, and talc.

[0036] Examples of acidulants include citric acid, tartaric acid, malic acid, etc.

[0037] The foaming agent may be, for example, bilayer foam.

[0038] Examples of sweeteners include sucralose, sodium saccharin, dipotassium glycyrrhizinate, aspartame, stevia, and thaumatin.

[0039] Examples of the flavoring include lemon, lemon-lime, orange, and menthol.

[0040] Examples of coloring agents include ferric oxide, yellow ferric oxide, black ferric oxide, titanium oxide, Food Yellow No. 4, Food Yellow No. 5, Food Red No. 3, Food Red No. 102, Food Blue No. 3, and the like.

[0041] Examples of buffering agents include citric acid, succinic acid, fumaric acid, tartaric acid, ascorbic acid or a salt thereof, glutamic acid, glutamine, glycine, aspartic acid, alanine, arginine or a salt thereof, magnesium oxide, zinc oxide, magnesium hydroxide, phosphoric acid, boric acid or a salt thereof, and the like.

[0042] Examples of the antioxidant include ascorbic acid, dibutylhydroxytoluene, and propyl gallate.

[0043] The blending amount is not particularly limited as long as it does not affect the achievement of the desired effects of the present invention.

[0044] The pharmaceutical composition of the present invention includes tablets. Tablets include plain tablets and film-coated tablets. The tablets may be orally disintegrating tablets. The pharmaceutical composition of the present invention can be manufactured by a normal tablet manufacturing method using granulation obtained by a predetermined method. More specifically, for example, sitagliptin phosphate anhydride and excipients are put into a fluidized bed granulation dryer, heated while fluidizing, a predetermined amount of a solution in which a binder is dissolved in water is sprayed, and dried to obtain a granulation. Sitagliptin phosphate anhydride, excipients, and binders can also be put into a fluidized bed granulation dryer, heated while fluidizing, a predetermined amount of purified water is sprayed, and dried to obtain a granulation. The granulation is sized by a granulation machine, and a disintegrant, a lubricant, and other additives as necessary are added to the obtained granulation, and mixed to obtain a powder for tableting. The obtained powder for tableting is tableted by a tableting machine while spraying a lubricant using an external lubricating device to obtain plain tablets.

[0045] In another embodiment, sitagliptin phosphate anhydrous, a low melting point substance, and other additives as required are put into a fluidized bed granulation dryer, heated while fluidized to melt the low melting point substance, and after the temperature reaches the melting point of the low melting point substance or higher, a sufficient amount is granulated to obtain a granulated product. The granulated product is sized using a granulator, and excipients, disintegrants, binders, flow agents, lubricants, and other additives as required are added to the granulated product obtained, and mixed to obtain a powder for tableting. The obtained powder for tableting is tableted using a tablet press to obtain plain tablets. During tableting, tableting may be performed while spraying a lubricant using an external lubricating device.

[0046] If necessary, a film coating liquid is sprayed onto the uncoated tablets to perform film coating. EXAMPLES

[0047] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to the following examples in any way.

[0048] The pharmaceutical compositions (tablets) of Examples 1 and 2 and Comparative Examples 1 to 3 were produced as follows. The formulations for each sample are shown in Tables 1 and 2. EXAMPLES

[0049] 155.1 g of sitagliptin phosphate anhydrous, 189.9 g of D-mannitol (manufactured by Rocket Japan Co., Ltd.; Pearitol (registered trademark) 50C), and 42.5 g of low-substituted hydroxypropyl cellulose (manufactured by Shin-Etsu Chemical Co., Ltd.; LH-21) were charged into a fluidized bed granulator (manufactured by Powrex Co., Ltd.; MP-01), granulated with a solution in which 12.5 g of hydroxypropyl cellulose (manufactured by Nippon Soda Co., Ltd.; HPC-L) was dissolved in 250 g of water, and then dried to obtain a granulated product. The granulated product was sieved through a sieve with an opening of 710 μm to obtain a sized product. A powder for tableting was prepared by mixing 320 g of the sized product, 10 g of croscarmellose sodium (ND-200, manufactured by Nichirin Chemical Industry Co., Ltd.), and 10 g of sodium stearyl fumarate (PRUV (registered trademark), manufactured by JRS PHARMA). The powder was compressed into tablets using a rotary tableting machine (VEL5, manufactured by Kikusui Seisakusho Co., Ltd.) and an external lubricating device (ELS-P1, manufactured by Kikusui Seisakusho Co., Ltd.) while spraying magnesium stearate (magnesium stearate (vegetable), manufactured by Taihei Chemical Industry Co., Ltd.) onto the mortar and pestle surfaces, to obtain irregularly shaped tablets measuring 9.0 × 3.7 mm and having a tablet mass of 85 mg. EXAMPLES

[0050] 155.1 g of sitagliptin phosphate anhydrous, 0.9 g of light anhydrous silicic acid (manufactured by Freund Corporation; Adsolider (registered trademark) 101), and 15.5 g of glycerin monostearate (manufactured by Riken Vitamin Co., Ltd.; Rikemal (registered trademark) S-100P) were placed in a fluidized bed granulator (manufactured by Powrex Corporation; MP-01), and heated while fluidizing with an inlet air temperature set to 90°C, to melt the glycerin monostearate and granulate it. After granulation, the mixture was thoroughly cooled to obtain a granulated product. The granulated product was sized using a sieving machine (manufactured by Dalton Corporation; P-04S) equipped with a mesh screen with an opening of 100 μm to obtain a sized product. The tablet powder was prepared by mixing 68.6 g of the sized product, 59 g of D-mannitol (Merck Co., Ltd.; Partec (registered trademark) M100), 25.6 g of low-substituted hydroxypropyl cellulose (Shin-Etsu Chemical Co., Ltd.; LH-11), 5 g of croscarmellose sodium (Nichirin Chemical Co., Ltd.; ND-200), 6.8 g of hydroxypropyl cellulose (Nippon Soda Co., Ltd.; HPC-SSL-SFP), 1.6 g of light anhydrous silicic acid (Freund Corporation; Adsolider (registered trademark) 101), and 3.4 g of sodium stearyl fumarate (JRS PHARMA; PRUV (registered trademark)). The mixture was compressed into tablets using a rotary tablet press (Kikusui Seisakusho Co., Ltd.; VEL5) to obtain irregular tablets with a tablet mass of 85 mg and a size of 9.0 × 3.7 mm.

[0051] <Comparative Example 1> 155.1 g of sitagliptin phosphate anhydrous, 189.9 g of D-mannitol (manufactured by Rocket Japan Co., Ltd.; Pearitol (registered trademark) 50C), and 42.5 g of low-substituted hydroxypropyl cellulose (manufactured by Shin-Etsu Chemical Co., Ltd.; LH-21) were charged into a fluidized bed granulator (manufactured by Powrex Co., Ltd.; MP-01), granulated with a solution in which 12.5 g of hydroxypropyl cellulose (manufactured by Nippon Soda Co., Ltd.; HPC-L) was dissolved in 250 g of water, and then dried to obtain a granulated product. The granulated product was sieved through a sieve with an opening of 710 μm to obtain a sized product. A powder for tableting was prepared by mixing 320 g of the sized product, 10 g of croscarmellose sodium (ND-200, manufactured by Nichirin Chemical Industry Co., Ltd.), and 10 g of sodium stearyl fumarate (PRUV (registered trademark), manufactured by JRS PHARMA). The powder was tableted using a rotary tableting machine (VEL5, manufactured by Kikusui Seisakusho Co., Ltd.) to obtain irregularly shaped tablets measuring 9.0 × 3.7 mm and having a tablet mass of 85 mg.

[0052] <Comparative Example 2> A powder for tableting was prepared by mixing 31.02 g of sitagliptin phosphate anhydrous, 31.03 g of anhydrous calcium hydrogen phosphate (manufactured by Fuji Chemical Industry Co., Ltd.; Fujicalin (registered trademark) SG), 1 g of light anhydrous silicic acid (manufactured by EVONIK; AEROSIL (registered trademark) 200), 31.95 g of crystalline cellulose (manufactured by Asahi Kasei Corporation; CEOLUS (registered trademark) UF-702), 3 g of croscarmellose sodium (manufactured by Nichirin Chemical Industry Co., Ltd.; ND-200), and 2 g of magnesium stearate (manufactured by Taihei Chemical Industry Co., Ltd.; magnesium stearate (light)), and the mixture was tableted using a rotary tableting machine (manufactured by Kikusui Seisakusho; VEL5) to obtain circular tablets with a tablet mass of 100 mg and a diameter of 6.0 mm.

[0053] <Comparative Example 3> Sitagliptin phosphate anhydrous 31.02 g, anhydrous calcium hydrogen phosphate (Fuji Chemical Industry Co., Ltd.; Fujicalin SG) 31.03 g, light anhydrous silicic acid (EVONIK; AEROSIL (registered trademark) 200) 1 g, crystalline cellulose (Asahi Kasei Co., Ltd.; CEOLUS (registered trademark) UF-702) 31.95 g, croscarmellose sodium (Nichirin Chemical Industry Co., Ltd.; ND-200) 3 g, maltose stearate The powder for tableting was prepared by mixing with 2 g of magnesium (Taihei Chemical Industry Co., Ltd.; magnesium stearate (light)). The powder was compressed into tablets using a rotary tableting machine (Kikusui Seisakusho; VEL5) and an external lubricating device (Kikusui Seisakusho; ELS-P1) while spraying magnesium stearate (Taihei Chemical Industry Co., Ltd.: magnesium stearate (vegetable)) onto the mortar and pestle surfaces, to obtain circular tablets with a tablet mass of 100 mg and a diameter of 6.0 mm.

[0054] [Table 1]

[0055] [Table 2]

[0056] <Test Example 1: Evaluation of Sticking> The appearance of the punch and the plain tablet after the completion of tableting in the comparative example and the example was visually checked to confirm the presence or absence of sticking. Specifically, the presence or absence of gloss on the tablet surface after tableting, and the presence or absence of adhesion and cloudiness on the surface of the compression molded part of the punch were confirmed. The evaluation results are shown in Table 3.

[0057] [Table 3]

[0058] The presence or absence of adhesion and cloudiness on the tablet surfaces and the surface of the compression molded part of the punch after tableting was checked. As a result, sticking was confirmed in Comparative Example 1 (fluidized bed granulation method only), Comparative Example 2 (direct compression method only), and Comparative Example 3 (direct compression method using an external lubricating device), but sticking was improved in Example 1 (fluidized bed granulation method using an external lubricating device) and Example 2 (melt granulation method).

Claims

1. A process for granulating a mixture containing sitagliptin phosphate anhydrous and one or more additives, characterized in that the granulation method is a melt granulation method; mixing the obtained granules with additives; A step of compressing the obtained mixture to obtain plain tablets. A method for producing a pharmaceutical composition comprising:

2. A process for granulating a mixture containing sitagliptin phosphate anhydrous and one or more additives, characterized in that the granulation method is a fluidized bed granulation method; mixing the obtained granules with additives; A process in which the obtained mixture is pre-applied with a lubricant on the surface of the punch and the wall of the die of the compression molding machine without mixing with other ingredients, and compressed and molded by the external lubrication method to obtain plain tablets. A method for producing a pharmaceutical composition comprising:

3. 2. The method according to claim 1, wherein one of the additives is a low melting point substance and the granules are produced by a melt granulation method.

4. The method according to claim 3, wherein the low melting point substance is glycerol monostearate.

5. The method according to any one of claims 1 to 2, wherein the pharmaceutical composition is a tablet.

Citation Information

Patent Citations

  • Novel crystalline form of phosphate of dipeptidyl peptidase-IV inhibitors

    JP2007504230A

  • Solid preparation containing sitagliptin or salt thereof

    JP2019172672A

  • Solid preparation

    JP2020121950A